Managing Pain without Addiction
Ketan Mehta, founder and CEO of Tris Pharma, discusses its experimental opiod Cebranopadol, how it modulates the addictive potential by targeting two receptors at once, and its potential to address the opioid crisis.
Ketan Mehta, founder and CEO of Tris Pharma, discusses its experimental opiod Cebranopadol, how it modulates the addictive potential by targeting two receptors at once, and its potential to address the opioid crisis.